nav mail map-pin
Caelus Health announces first closing of a Series A financing round to advance microbiota-based therapeutics for cardio-metabolic disorders

Caelus Health announces first closing of a Series A financing round to advance microbiota-based therapeutics for cardio-metabolic disorders

26 January | Caelus Health

Caelus Health announces first closing of a Series A financing round to advance microbiota-based therapeutics for cardio-metabolic disorders

Amsterdam, the Netherlands, January 26th 2017 Caelus Health has secured EUR 2.5 million in a Series A investment round, enabling the company to advance its pipeline of microbiota-based products for early intervention in cardio-metabolic disease.

Caelus Health is one of the first companies fully dedicated to the clinical development of microbiota-based products for early intervention in cardio-metabolic disease. Caelus was founded in 2014 by prof. Max Nieuwdorp (Academic Medical Centre, AMC, Amsterdam) and prof. Willem M. De Vos (Wageningen University), based on the initial work with fecal transplant studies in the AMC.

In recent years it has been demonstrated that alterations in intestinal microbiota are associated with obesity and insulin resistance. Caelus is developing a pipeline of clinical products for the early treatment and prevention of cardio-metabolic diseases including metabolic syndrome, fatty liver disease and diabetes mellitus.

The investment round is led by Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and supported by founding investor Life Sciences Fund Amsterdam (LSFA). In addition, Caelus obtained a EUR 1.9 million innovation credit from the Dutch Ministry of Economic Affairs. Caelus will set-up capabilities to support its product development platform and advance its pipeline of microbiota-based products.

Luc Sterkman MD, CEO of Caelus states: “We are delighted to announce the support from a leading strategic life sciences investor and to have the continued support from our founding investor. This allows Caelus to boost the efforts of the company in developing a new class of products based on microbiota and addressing a strong need for early interventions in diabetes and other metabolic diseases.”

Caelus is amongst the first companies joining Johnson & Johnson Innovation, JLINX, managed and supported by Bioqube Ventures and is leveraging the full potential of this new investment and incubation model: venture financing by JJDC, the access to microbiome subject matter expertise through the Janssen Human Microbiome Institute (JHMI) and access to the capabilities at the Janssen Research & Development, LLC site in Beerse, Belgium.

Dirk Gevers, Global Head of JHMI, will join the Scientific Advisory Board of Caelus.